InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.360 0.01 (2.70%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$110 Quarterly Activities/Appendix 4C Cash Flow Report 20 Oct 2023 10:28AM $0.445 $0.360 fallen by 19.10%
$110 Application for quotation of securities - RCE 13 Oct 2023 10:19AM $0.475 $0.360 fallen by 24.21%
$110 Correction to Notice of Annual General Meeting 13 Oct 2023 9:17AM $0.460 $0.360 fallen by 21.74%
$110 Notice of Annual General Meeting/Proxy Form 9 Oct 2023 9:04AM $0.455 $0.360 fallen by 20.88%
$110 Change of Director's Interest Notices 6 Oct 2023 3:11PM $0.460 $0.360 fallen by 21.74%
$110 Correction to ASX Announcement 5 Oct 2023 6:32PM $0.430 $0.360 fallen by 16.28%
$110 Placement of Entitlement Offer Shortfall 5 Oct 2023 2:53PM $0.440 $0.360 fallen by 18.18%
$110 Appendix 4G 29 Sep 2023 4:50PM $0.485 $0.360 fallen by 25.77%
$110 Annual Report to Shareholders 29 Sep 2023 4:40PM $0.485 $0.360 fallen by 25.77%
$110 Entitlement Offer - Announcement of Results 29 Sep 2023 9:52AM $0.445 $0.360 fallen by 19.10%
$110 Application for quotation of securities - RCE 29 Sep 2023 9:48AM $0.445 $0.360 fallen by 19.10%
$110 Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial 22 Sep 2023 10:40AM $0.475 $0.360 fallen by 24.21%
$110 Becoming a substantial holder 20 Sep 2023 2:36PM $0.470 $0.360 fallen by 23.40%
$110 2023 Annual General Meeting 18 Sep 2023 5:07PM $0.500 $0.360 fallen by 28%
$110 Cleansing Statement 18 Sep 2023 10:48AM $0.505 $0.360 fallen by 28.71%
$110 Application for quotation of securities - RCE 18 Sep 2023 10:33AM $0.515 $0.360 fallen by 30.10%
$110 Entitlement Offer - Notification to Ineligible Shareholders 15 Sep 2023 8:48AM $0.490 $0.360 fallen by 26.53%
$110 Entitlement Offer Booklet 15 Sep 2023 8:47AM $0.490 $0.360 fallen by 26.53%
$110 Cleansing Statement 11 Sep 2023 7:03PM $0.520 $0.360 fallen by 30.77%
$110 Application for quotation of securities - RCE 11 Sep 2023 6:50PM $0.520 $0.360 fallen by 30.77%
$110 Cleansing Notice - Entitlement Offer 11 Sep 2023 10:04AM $0.650 $0.360 fallen by 44.62%
$110 Proposed issue of securities - RCE 11 Sep 2023 9:52AM $0.650 $0.360 fallen by 44.62%
$110 Placement and Entitlement Offer 11 Sep 2023 9:52AM $0.650 $0.360 fallen by 44.62%
$110 Trading Halt 8 Sep 2023 9:41AM $0.650 $0.360 fallen by 44.62%
$110 Opening R&D Address at World AMR Congress 8 Sep 2023 9:07AM $0.650 $0.360 fallen by 44.62%

201 - 225 of 729 results

Page 9 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.